Gilead Sciences, Inc. has reached settlement agreements with generic pharmaceutical manufacturers Lupin Ltd., Cipla Ltd., and Laurus Labs Ltd., effectively delaying the entry of generic versions of its HIV treatment, Biktarvy, into the U.S. market until April 1, 2036. ([investing.com](https://www.investing.com/news/sec-filings/gilead-sciences-reaches-settlement-on-biktarvy-patent-litigation-with-generics-93CH-4272663?utm_source=openai))
Biktarvy, a single-tablet regimen combining bictegravir (50 mg), emtricitabine (200 mg), and tenofovir alafenamide (25 mg), is a cornerstone of Gilead’s HIV portfolio. The settlements, which include standard acceleration provisions, ensure that no generic equivalents will be available in the U.S. before the specified date. ([streetinsider.com](https://www.streetinsider.com/SEC%2BFilings/Form%2B8-K%2BGILEAD%2BSCIENCES%2C%2BINC.%2BFor%3A%2BOct%2B06/25422218.html?utm_source=openai))
This development follows Gilead’s previous legal actions to protect its intellectual property. In February 2022, the company resolved a global patent dispute with ViiV Healthcare concerning bictegravir, the novel component in Biktarvy. As part of that settlement, Gilead agreed to a one-time payment of $1.25 billion and ongoing royalties of 3% on future U.S. sales of Biktarvy until 2027. ([gilead.com](https://www.gilead.com/news-and-press/company-statements/gilead-announces-global-resolution-of-bictegravir-patent-dispute-with-viiv-healthcare?utm_source=openai))
The recent settlements have had a positive impact on Gilead’s stock performance. Following the announcement, shares of Gilead Sciences rose by 4.5%, reflecting investor confidence in the company’s ability to maintain market exclusivity for Biktarvy. ([investing.com](https://www.investing.com/news/stock-market-news/gilead-stock-rises-after-settling-biktarvy-patent-disputes-4272803?utm_source=openai))
However, Gilead has faced legal challenges regarding its business practices. In April 2025, the company agreed to pay $202 million to settle claims that it provided kickbacks to doctors to promote its HIV drugs, including Biktarvy. The U.S. Attorney’s Office in Manhattan alleged that from 2011 to 2017, Gilead offered improper incentives, such as speaker fees and lavish meals, to encourage prescriptions of its medications. ([cnbc.com](https://www.cnbc.com/2025/04/29/gilead-sciences-agrees-to-pay-202-million-to-settle-claims-of-kickbacks-to-doctors-for-hiv-drug-prescriptions.html?utm_source=openai))
Additionally, in October 2024, Gilead signed royalty-free licensing agreements with six generic drug manufacturers to produce and sell cheaper versions of its HIV prevention medicine, lenacapavir, in 120 low and lower-middle-income countries. This initiative aims to improve access to HIV treatments in regions heavily affected by the virus. ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/gilead-signs-deals-with-6-generic-drugmakers-sell-hiv-drug-low-income-countries-2024-10-02/?utm_source=openai))
These strategic legal and business maneuvers underscore Gilead’s commitment to maintaining its leadership in the HIV treatment market while addressing global health challenges.